eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
1/2024
vol. 49
 
Share:
Send email
Share:
Review paper

Immunological relationship between Helicobacter pylori and anti-tumor necrosis factor α agents in inflammatory bowel disease

Han Huang
1
,
Chenxiao Gan
1
,
Yan Cai
2, 3, 4
,
Lingkang Wu
5

1.
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, China
2.
School of Basic Medical Sciences, Zhejiang Chinese Medical University,
3.
Key Laboratory of Blood-stasis-toxin Syndrome of Zhejiang Province, China
4.
Traditional Chinese Medicine “Preventing Disease” Wisdom Health Project Research Center of Zhejiang, China
5.
The Second Affiliated Hospital of Zhejiang Chinese Medical University, China
Cent Eur J Immunol 2024; 49 (1): 70-76
DOI: https://doi.org/10.5114/ceji.2024.136376
Online publish date: 2024/03/25
Article file
- Immunological relationship (1).pdf  [0.58 MB]
Get citation
 
PlumX metrics:
 
1. Lee JW, Eun CS (2022): Inflammatory bowel disease in Korea: epidemiology and pathophysiology. Korean J Intern Med 37: 885-894.
2. Mak WY, Zhao M, Ng SC, Burisch J (2020): The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol 35: 380-389.
3. Agrawal M, Jess T (2022): Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United European Gastroenterol J 10: 1113-1120.
4. Damião A, de Azevedo MFC, Carlos AS, et al. (2019): Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 25: 1142-1157.
5. Veauthier B, Hornecker JR (2018): Crohn’s disease: diagnosis and management. Am Fam Physician 98: 661-669.
6. Jang DI, Lee AH, Shin HY, et al. (2021): The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci 22: 2719.
7. Atreya R, Neurath MF (2022): IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality. J Crohns Colitis 16: ii54-ii63.
8. Robinson K, Atherton JC (2021): The Spectrum of Helicobacter-mediated diseases. Annu Rev Pathol 16: 123-144.
9. Sharndama HC, Mba IE (2022): Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol 53: 33-50.
10. Wang L, Cao ZM, Zhang LL, et al. (2022): Helicobacter pylori and autoimmune diseases: involving multiple systems. Front Immunol 13: 833424.
11. Bai X, Jiang L, Ruan G, et al. (2022): Helicobacter pylori may participate in the development of inflammatory bowel disease by modulating the intestinal microbiota. Chin Med J (Engl) 135: 634-638.
12. Guan Q (2019): A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019: 7247238.
13. Ramos GP, Papadakis KA (2019): Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc 94: 155-165.
14. Kim HJ, Shah SC, Hann HJ, et al. (2021): Familial risk of inflammatory bowel disease: a population-based cohort study in South Korea. Clin Gastroenterol Hepatol 19: 2128-2137.e15.
15. Pittayanon R, Lau JT, Leontiadis GI, et al. (2020): Differences in gut microbiota in patients with vs without inflammatory bowel diseases: A Systematic Review. Gastroenterology 158: 930-946.e1.
16. Zhou L, Zhang M, Wang Y, et al. (2018): Faecalibacterium prausnitzii produces butyrate to maintain Th17/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. Inflamm Bowel Dis 24: 1926-1940.
17. Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM (2019): Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev 32: e00060-18.
18. Ni J, Wu GD, Albenberg L, Tomov VT (2017): Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol 14: 573-584.
19. Fang H, Fu L, Wang J (2018): Protocol for fecal microbiota transplantation in inflammatory bowel disease: a systematic review and meta-analysis. Biomed Res Int 2018: 8941340.
20. Saez A, Herrero-Fernandez B, Gomez-Bris R, et al. (2023): Pathophysiology of inflammatory bowel disease: innate immune system. Int J Mol Sci 24: 1526.
21. Chen Y, Cui W, Li X, Yang H (2021): Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease. Front Immunol 12: 761981.
22. Ahluwalia B, Moraes L, Magnusson MK, Öhman L (2018): Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol 53: 379-389.
23. Porter RJ, Kalla R, Ho GT (2020): Ulcerative colitis: recent advances in the understanding of disease pathogenesis. F1000Res 9: F1000 Faculty Rev-294.
24. Kofla-Dłubacz A, Pytrus T, Akutko K, et al. (2022): Etiology of IBD-is it still a mystery? Int J Mol Sci 23: 12445.
25. Slevin SM, Egan LJ (2015): New insights into the mechanisms of action of anti-tumor necrosis factor- monoclonal antibodies in inflammatory bowel disease. Inflamm Bowel Dis 21: 2909-2920.
26. Ruder B, Atreya R, Becker C (2019): Tumour necrosis factor alpha in intestinal homeostasis and gut related diseases. Int J Mol Sci 20: 1887.
27. Jung MK, Lee JS, Kwak JE, Shin EC (2019): Tumor necrosis factor and regulatory T cells. Yonsei Med J 60: 126-131.
28. Billmeier U, Dieterich W, Neurath MF, Atreya R (2016): Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 22: 9300-9313.
29. Vos AC, Wildenberg ME, Duijvestein M, et al. (2011): Anti- tumor necrosis factor- antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 140: 221-230.
30. Castaño-Rodríguez N, Kaakoush NO, Lee WS, Mitchell HM (2017): Dual role of Helicobacter and Campylobacter species in IBD: a systematic review and meta-analysis. Gut 66: 235-249.
31. Engler DB, Leonardi I, Hartung ML, et al. (2015): Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18. Inflamm Bowel Dis 21: 854-861.
32. Piovani D, Danese S, Peyrin-Biroulet L, et al. (2019): Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology 157: 647-659.e4.
33. Zhong Y, Zhang Z, Lin Y, Wu L (2021): The relationship between helicobacter pylori and inflammatory bowel disease. Arch Iran Med 24: 317-325.
34. Yang L, Zhang J, Xu J, et al. (2019): Helicobacter pylori infection aggravates dysbiosis of gut microbiome in children with gastritis. Front Cell Infect Microbiol 9: 375.
35. Guo Y, Zhang Y, Gerhard M, et al. (2020): Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut 69: 1598-1607.
36. Tepler A, Narula N, Peek RM, Jr., et al. (2019): Systematic review with meta-analysis: association between Helicobacter pylori CagA seropositivity and odds of inflammatory bowel disease. Aliment Pharmacol Ther 50: 121-131.
37. Yu Y, Zhu S, Li P, et al. (2018): Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. Cell Death Dis 9: 961.
38. Shirzad-Aski H, Besharat S, Kienesberger S, et al. (2021): Association between Helicobacter pylori colonization and inflammatory bowel disease: a systematic review and meta- Analysis. J Clin Gastroenterol 55: 380-392.
39. Yamamoto-Furusho JK, Fonseca-Camarillo G, Barrera- Ochoa CA, Furuzawa-Carballeda J (2020): Synthesis of interleukin-10 in patients with ulcerative colitis and Helicobacter pylori infection. Gastroenterol Res Pract 2020: 4171083.
40. Lin KD, Chiu GF, Waljee AK, et al. (2019): Effects of anti- Helicobacter pylori therapy on incidence of autoimmune diseases, including inflammatory bowel diseases. Clin Gastroenterol Hepatol 17: 1991-1999.
41. Abd El-Wahab EW, Youssef EI, Hassouna E (2022): Helicobacter pylori infection in patients with inflammatory bowel diseases: a single-centre, prospective, observational study in Egypt. BMJ Open 12: e057214.
42. Deng G, Song X, Fujimoto S, et al. (2019): Foxp3 post-translational modifications and Treg suppressive activity. Front Immunol 10: 2486.
43. Cho KY, Cho MS, Seo JW (2012): Foxp3+ regulatory T cells in children with helicobacter pylori infection. Pediatr Dev Pathol 15: 118-126.
44. Georgiev P, Charbonnier LM, Chatila TA (2019): Regulatory T cells: the many faces of Foxp3. J Clin Immunol 39: 623-640.
45. Neumann C, Scheffold A, Rutz S (2019): Functions and regulation of T cell-derived interleukin-10. Semin Immunol 44: 101344.
46. Koelink PJ, Bloemendaal FM, Li B, et al. (2020): Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut 69: 1053-1063.
47. Hakim MS, Ding S, Chen S, et al. (2018): TNF-α exerts potent anti-rotavirus effects via the activation of classical NF-κB pathway. Virus Res 253: 28-37.
48. Souza RF, Caetano MAF, Magalhães HIR, Castelucci P (2023): Study of tumor necrosis factor receptor in the inflammatory bowel disease. World J Gastroenterol 29: 2733-2746.
49. Mommersteeg MC, Simovic I, Yu B, et al. (2022): Autophagy mediates ER stress and inflammation in Helicobacter pylori- related gastric cancer. Gut Microbes 14: 2015238.
50. Triantafillidis JK, Gikas A, Merikas E (2014): Treatment of inflammatory bowel disease patients with anti-TNF-α factors and immunosuppressives does not influence the prevalence of Helicobacter pylori infection. Indian J Gastroenterol 33: 383-384.
Copyright: © 2024 Polish Society of Experimental and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.